UNIVERSITY OF UTAH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1850-02-28

Employees: 10K

Market Cap: -

Website: http://www.utah.edu

Clinical Trials

Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers

Early Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Amiloride

First Posted Date: 2019-11-29

Last Posted Date: 2023-03-08

Lead Sponsor: University of Utah

Target Recruit Count: 15

Registration Number: NCT04181008

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Phase 3

Recruiting

Conditions: Hydrocephalus

Interventions: Procedure: Endoscopic Third Ventriculostomy with Choroid Plexus Cauterization (ETV+CPC)
Device: Ventriculoperitoneal Shunt

First Posted Date: 2019-11-26

Last Posted Date: 2024-06-25

Lead Sponsor: University of Utah

Target Recruit Count: 176

Registration Number: NCT04177914

Locations: 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Wolfson Children's Hospital, Jacksonville, Florida, United States

and more 16 locations

Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

Phase 2

Suspended

Conditions: Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Oral Cavity Carcinoma
Recurrent Hypopharyngeal Carcinoma
Recurrent Nasal Cavity and Paranasal Sinus Carcinoma
Stage III Laryngeal Cancer AJCC v8
Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IVA Laryngeal Cancer AJCC v8
Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Recurrent Oral Cavity Carcinoma
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Interventions: Drug: Celecoxib
Other: Placebo
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-11-14

Last Posted Date: 2024-02-13

Lead Sponsor: University of Utah

Target Recruit Count: 60

Registration Number: NCT04162873

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer Metastatic

Interventions: Drug: Durvalumab
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2019-11-14

Last Posted Date: 2024-05-08

Lead Sponsor: University of Utah

Target Recruit Count: 84

Registration Number: NCT04163432

Locations: 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States

Intraperitoneal Oxaliplatin in Combo w IV mFOLFIRI for Peritoneal Carcinomatosis From Colorectal & Appendiceal Cancer

Phase 1

Terminated

Conditions: Colorectal Cancer
Appendiceal Cancer
Peritoneal Carcinoma

Interventions: Drug: Oxaliplatin
Drug: mFOLFIRI

First Posted Date: 2019-11-08

Last Posted Date: 2021-09-27

Lead Sponsor: University of Utah

Target Recruit Count: 1

Registration Number: NCT04158349

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

Phase 1

Completed

Conditions: Gastrointestinal Neoplasms

Interventions: Drug: Ulixertinib
Drug: Hydroxychloroquine

First Posted Date: 2019-10-30

Last Posted Date: 2024-11-18

Lead Sponsor: University of Utah

Target Recruit Count: 16

Registration Number: NCT04145297

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC

Phase 1

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder)

Interventions: Drug: Ipilimumab
Drug: Osimertinib

First Posted Date: 2019-10-28

Last Posted Date: 2024-11-06

Lead Sponsor: University of Utah

Target Recruit Count: 24

Registration Number: NCT04141644

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Human Amniotic Membrane to Decrease Post Operative Atrial Fibrillation

Early Phase 1

Completed

Conditions: Atrial Fibrillation

Interventions: Biological: Human Amniotic Membrane

First Posted Date: 2019-10-17

Last Posted Date: 2024-12-06

Lead Sponsor: University of Utah

Target Recruit Count: 27

Registration Number: NCT04130061

Locations: 🇺🇸
University of Utah, Salt Lake City, Utah, United States

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

Phase 1

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Nivolumab

First Posted Date: 2019-09-30

Last Posted Date: 2024-06-13

Lead Sponsor: University of Utah

Target Recruit Count: 36

Registration Number: NCT04109729

Locations: 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States

Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)

Phase 1

Recruiting

Conditions: Borderline Resectable Pancreatic Adenocarcinoma
Locally Advanced Unresectable Pancreatic Adenocarcinoma
Stage II Pancreatic Cancer AJCC v8
Stage IIA Pancreatic Cancer AJCC v8
Stage IIB Pancreatic Cancer AJCC v8
Stage III Pancreatic Cancer AJCC v8
Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions: Radiation: Hypofractionated Radiation Therapy
Drug: Losartan
Drug: Losartan Potassium
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-09-27

Last Posted Date: 2024-05-29

Lead Sponsor: University of Utah

Target Recruit Count: 23

Registration Number: NCT04106856

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

Home Terms & Conditions Privacy Policy